



Editorial

Antibacterial activities of Meloxicam, Ibuprofen and Diclofenac: an Additional Approach to their Immunological Therapy

Professor Ali Abdul Hussein S. AL-Janabi¹

¹Department of Microbiology, College of Medicine, University of Karbala, Iraq

Editor-In-Chief

<https://doi.org/10.70863/karbalajm.v18i1.3827>

Non-steroidal anti-inflammatory drugs (NSAIDs) are anti-inflammatory, antipyretic, and analgesic drugs that are frequently utilized in the treatment of musculoskeletal disorders, mild to moderate pain, and fever [1]. Such immunological activities are not the sole method by which NSAIDs can prevent diseases. They also have direct potential inhibitory effects on several types of organisms. Antibacterial activities of some NSAIDs have been observed against different pathogenic bacteria.

In aspect of meloxicam activity, the biological activities of *Pseudomonas aeruginosa* (PAO1), such as biofilm formation, motility, matrix synthesis, and expression of quorum-sensing genes, are inhibited by meloxicam [2]. Another strain of *P. aeruginosa* showed resistance to meloxicam even though all other strains of Gram-negative and Gram-negative bacteria were sensitive to it [3]. Production of staphyloxanthin, one of the virulence factors produced by *Staphylococcus aureus*, and its encoded genes, was inhibited by 47-59 µg/mL of meloxicam or diclofenac [4]. Antibacterial activities against Gram-positive and Gram-negative bacteria can be achieved by synthesizing synthetic ligand complexes from meloxicam with glycine [5]. Complex type A in that study had the lowest MIC on *Listeria* spp. and *Escherichia coli* (10.8 µg/mL), making it the most antibacterial agent.

In addition to meloxicam, ibuprofen, and diclofenac have antibacterial effects on several clinical bacterial isolates. Diclofenac could have more antibacterial effects on bacteria than ibuprofen. Of four NSAIDs, diclofenac had strong antibacterial action on the methicillin-resistant *S. aureus* (MRSA) strain and other ten clinical isolates of bacteria, followed by ibuprofen, which only failed to affect *Bacillus cereus* [6]. The

study of the antibacterial action of different pharmaceutical drugs on 89 strains of Gram-negative bacteria showed that 5 of 12 NSAIDs have strong antibacterial activities on the bacterial species at MIC >3200 mg/L, including diclofenac (100%), acetylsalicylic acid (100%), and salicylamide (76%) [7]. Other members showed either lower activities, such as ibuprofen (35%) and naproxen (29%), or no activities, as with indomethacin, mefenamic acid, and meloxicam. *E. coli* strains isolated from the UTI were significantly inhibited by low concentrations of diclofenac (MIC₉₀, 256 µg/mL) compared to high concentrations of ibuprofen (MIC₉₀, 1024 µg/mL) [8]. Increasing the concentration of diclofenac may be required to inhibit resistant strains of bacteria, such as multidrug-resistant *Proteus mirabilis* [9]. However, the antibacterial action of diclofenac cannot hide the inhibitory effects of ibuprofen on different bacteria, particularly on Gram-positive bacteria, compared to Gram-negative bacteria [10]. Additionally, the antibacterial activity of NSAIDs can be affected by the pH value of the media, and any elevation in the pH above 7 can block these activities [10].

Multidisciplinary therapeutic uses of NSAIDs for treatment of immunological and antimicrobial diseases promote them to be the best choice in cases with serious infectious diseases. They could be an alternative to the antibiotics with low antibacterial action.

References

1. Babaei F, Mirzababaei M, Tavakkoli A, Nassiri-Asi M, Hosseinzadeh H. Can nonsteroidal anti-inflammatory drugs (NSAIDs) be repurposed for fungal infection? *Naunyn Schmiedebergs Arch Pharmacol.* 2024; 397:59-75.

2. She P, Wang Y, Luo Z, Chen L, Tan R, Wang Y, et al. Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by *Pseudomonas aeruginosa*. *MicrobiologyOpen*. 2018; 7:e545. <https://doi.org/10.1002/mbo3.545>.
3. Al-kuraishy HM, algareeb AI, Al-windy SA. Experimental antibacterial activity of selective cyclooxygenase antagonist. *IJPCBS*. 2013; 3:692-699.
4. Elmesseri RA, Saleh SE, Ghobish SA, Majrashi TA, Elsherif HM, Aboshanab KM. Diclofenac and meloxicam exhibited anti-virulence activities targeting staphyloxanthin production in methicillin-resistant *Staphylococcus aureus*. *Antibiotics*. 2023; 12, 277. <https://doi.org/10.3390/antibiotics12020277>.
5. Elshafie HS, Sadeek SA, Zordok WA, Mohamed AA. Meloxicam and study of their antimicrobial effects against phyto- and human pathogens. *Molecules*. 2021; 26, 1480. <https://doi.org/10.3390/molecules26051480>.
6. Chan EWL, Yee ZY, Raja I, Yap JKY. Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant *Staphylococcus aureus*. *J Glob Antimicrob Resist*. 2017; 10:70-74.
7. Laudy AE, Mrowka A, Krajewska J, Tyski S. The influence of efflux pump inhibitors on the activity of non-antibiotic NSAIDS against Gram-negative rods. *PLoS ONE*. 2016; 11(1): e0147131. DOI:10.1371/journal.pone.0147131.
8. Ahmed EF, Abd EI-Baky RM, Ahmed ABF, Fawzy NG, Aziz NA, Gad GFM. Evaluation of antibacterial activity of some non-steroidal anti-inflammatory drugs against *Escherichia coli* causing urinary tract infection. *African J Microbiol Res*. 2016; 10:1408-1416.
9. Ibrahim GJ, AL-Rubaii BAL. Antibacterial activity of some non-steroidal anti-inflammatory drugs against *Proteus mirabilis*. *Ibn Al-Haitham J Pure Appl Sci*. 2024; 37:9-18.
10. Elvers KT, Wright SJL. Antibacterial activity of the anti-inflammatory compound ibuprofen. *Letters Appl Microb*. 1995; 20:82-84.